Phase 2RecruitingINTERVENTIONAL
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
ClinicalTrials.gov · NCT05938712 · Registry updated: 2026-05-01
- Condition / research focus
- Kidney Transplant Recipients
- Sponsor
- University Health Network, Toronto
- Countries with listed sites
- Canada
- Registry dates and results
- Start: 2023-10-24. Completion: 2028-03-01 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Dapagliflozin 10 MG (drug) — also listed as: FARXIGA
- Semaglutide, 1.0 mg/mL (drug) — also listed as: OZEMPIC
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Toronto General Hospital
Toronto, Ontario, Canada
Site recruitment: Recruiting